126
126
160
160
153
153
145
145
148
148
151
151
76
76
83
83
72
72
65
65
2010
2001
Company (2.4K)University (109)Research Institution (38)Hospital (34)Investor (4)Foundation (3)
1 - 10 of 2,482
Sort by
Patent
Publication NumberUS 20180221446Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2017-09-08Publication Date2018-08-09
The present invention provides a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of…
Patent
Publication NumberEP 1626708 B1Filing StatusIssued PatentAvailabilityUnknownFiling Date2004-05-21Publication Date2017-11-29
Patent
Publication NumberEP 1631264 B8Filing StatusIssued PatentAvailabilityUnknownFiling Date2004-06-02Publication Date2017-05-24
Patent
Publication NumberUS 9598469Filing StatusIssued PatentAvailabilityUnknownFiling Date2013-12-26Publication Date2017-03-21
The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
Patent
Publication NumberEP 1596834 B1Filing StatusIssued PatentAvailabilityUnknownFiling Date2004-01-14Publication Date2016-11-30
Patent
Publication NumberEP 1531796 B1Filing StatusIssued PatentAvailabilityUnknownFiling Date2003-02-20Publication Date2016-09-28
Patent
Publication NumberUS 9393215Filing StatusIssued PatentAvailabilityUnknownFiling Date2006-12-01Publication Date2016-07-19
Disclosed herein are sterile-filtered lyophilized nanoparticle compositions which contain at least one biodegradable polymer, at least one surfactant, at least one cryoprotective agent and at least one antigen. Also disclosed are methods of making and using such compositions and kits supplying such compositions.
Patent
Publication NumberEP 1438074 B1Filing StatusIssued PatentAvailabilityUnknownFiling Date2002-10-03Publication Date2016-06-01
Patent
Publication NumberUS 20150361432Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2015-08-06Publication Date2015-12-17
The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA (dsRNA) molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering…
Patent
Publication NumberUS 9107831Filing StatusIssued PatentAvailabilityUnknownFiling Date2004-06-02Publication Date2015-08-18
Immunogenic compositions comprising microparticles with adsorbed toxoid antigen and/or polysaccharide-containing antigen are disclosed. The immunogenic microparticle compositions comprise (a) polymer microparticles comprising a biodegradable polymer; (b) an antigen adsorbed to the microparticles selected from (i) a toxoid antigen, such as a tetanus toxoid, a diphtheria toxoid, or a combination thereof, and/or (ii) a polysaccharide containing antigen, such as a Hib polysaccharide antigen, a Hi…
We found 2,482 documents that match your Search
Research Grants: 2
Patents: 2,314
Clinical Trials: 37
SEC Filings: 129

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in